BEIJING–(BUSINESS WIRE)–Jan 27, 2021–
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will release thirteen new research findings at the 21 st World Conference on Lung Cancer (WCLC), which will be held virtually from January 28 to 31. One of the research findings (Study 3713) was selected for a mini oral presentation.
Genetron Health joined hands with eight top Chinese hospitals to conduct in-depth analysis and research on a large-scale lung cancer cohort, leveraging the Genetron One-Step Seq Method and core products such as Onco Panscan TM. The research has achieved key findings in gene mutation and fusion feature mapping, immunotherapy marker detection, bioinformatics analysis, etc., laying the groundwork for further exploration of lung cancer diagnosis, treatment and the design of treatment solutions.
Exploring the characteristics of gene mutation
Seven studies (#1766, #2150, #2226, #2007, #1780, #1452, #835) on EGFR mutations, JAK family gene mutations, FGFR1-4 mutations, KIT activating mutations, mTOR signaling pathway mutations, and IDH1/2 mutations, respectively, were conducted to explore their mutation patterns and distribution characteristics in Chinese lung cancer patients, and to search for drug-resistant targets and effective solutions.
Exploring the characteristics of gene fusion
Study 3609 involved an in-depth analysis of 10 gene fusion patterns and distributions in the Chinese lung cancer population, as well as their co-occurrences with other driver mutations, in order to construct initial gene fusion mapping. Study 3601 focused on the prevalence and clinical benefit ratio of NTRK1 rare fusion in the Chinese lung cancer population.
Detecting immunotherapy markers
Study 3698 demonstrated the usage of KMT2C/D gene mutations as a positive predictor of the efficacy of non-small cell lung cancer (NSCLC) immunotherapy, indicating that patients with such gene mutations may benefit from immunotherapy. Study 3713 focused on the differences amongst DDR (DNA Damage Response) signaling pathway-related gene mutations in NSCLC and small cell lung cancer (SCLC), supporting the research of immunotherapy in the two patient groups.
Optimizing bioinformatics models
Based on six CpG sites, Study 2231 developed a random forest classification model, a new type of bioinformatics model, to distinguish early lung adenocarcinoma from benign nodules.
Rare case research
Study 3630 used Genetron’s One-Step Seq patented technology (Chinese Invention Patent No. ZL 201710218529.4) in the detection of a very rare patient with dual ROS1 fusion lung adenocarcinoma in a cohort of 180 people, demonstrating an efficacy greater than those of common diagnostic methods. In addition, the study noted the patient’s positive reaction to crizotinib, which indicates a direction for future research on the mechanism of this rare phenomenon.
“The thirteen research findings we are releasing at the WCLC, which focus on the characteristics of the Chinese lung cancer population, have made discoveries in multiple dimensions and demonstrated Genetron Health’s strong capabilities in the fundamental research of lung cancer genomics,” said Dr. Hai Yan, Co-founder and Chief Scientific Officer of Genetron Health. “The research findings regarding EGFR, JAK, FGFR and other mutation patterns, and drug resistance studies can enhance the development of more diverse and personalized medication strategies for patients. Gene fusion mapping can guide the design of more advanced and rich diagnostic products. The discovery of KMT2C/D mutations indicates more possibilities for lung cancer patients to benefit from immunotherapy treatments. In addition, the rare cases detected through Genetron Health’s patented research technology will draw more attention to and promote further research on relevant cancer diagnosis and treatment."
|ABSTRACT NUMBER||ABSTRACT TITLE|
|2226||Identification of FGFR Mutations in Chinese Lung Cancer Patients by Next-Generation Sequencing|
|3609||Exploration of the Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis|
|2150||Next generation sequencing reveals the genetic landscape of JAK family in Chinese lung cancer patients|
|1766||Comprehensive investigation of uncommon EGFR mutations in 14,429 Chinese lung cancer patients|
|1780||Next-generation sequencing guided the gene mutations associated with mTOR-inhibitors in Chinese lung cancer patients|
|3601||The prevalence of NTRK1 fusion in a Chinese lung cancer cohort|
|3630||A recommended one-step targeted sequencing technology for identification of a dual CD74-ROS1 in NSCLC|
|2231||Identification of DNA methylation markers to distinguish early-stage lung adenocarcinomas from benign pulmonary nodules|
|3713||DNA damage response gene alterations and their association with tumor mutation burden and response to immunotherapy in NSCLC and SCLC|
|3698||Association of KMT2C/D mutations with tumor mutation burden and response to immune checkpoint inhibitors in NSCLC|
|2007||Molecular Alterations of KIT Oncogene in a Large Cohort of Chinese Pan-Lung Cancer Patients|
|835||Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC|
|1452||A Large-Scale Survey of IDH Mutation in Chinese Patients With NSCLC|
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding research results, genomics exploration, bioinformatics model construction and optimization, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210127005381/en/
CONTACT: Media Relations
Mobile: +86 138-1079-1408
KEYWORD: CHINA ASIA PACIFIC
INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Genetron Holdings Limited
Copyright Business Wire 2021.
PUB: 01/27/2021 05:00 AM/DISC: 01/27/2021 05:01 AM